Weaver Consulting Group Grows Stock Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO)

Weaver Consulting Group increased its stake in Fortress Biotech, Inc. (NASDAQ:FBIO) by 33.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,998 shares of the biopharmaceutical company’s stock after buying an additional 5,700 shares during the period. Weaver Consulting Group owned 0.08% of Fortress Biotech worth $47,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. PVG Asset Management Corp boosted its holdings in Fortress Biotech by 140.1% in the third quarter. PVG Asset Management Corp now owns 373,790 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 218,115 shares in the last quarter. Geode Capital Management LLC boosted its stake in Fortress Biotech by 28.8% in the 3rd quarter. Geode Capital Management LLC now owns 168,607 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 37,736 shares in the last quarter. Integrated Wealth Concepts LLC boosted its stake in Fortress Biotech by 68.2% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 18,700 shares in the last quarter. Atria Investments Inc grew its position in Fortress Biotech by 58.4% during the 3rd quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 26,351 shares during the last quarter. Finally, Shikiar Asset Management Inc. increased its stake in Fortress Biotech by 4.4% during the 3rd quarter. Shikiar Asset Management Inc. now owns 235,969 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 96.51% of the company’s stock.

Fortress Biotech Stock Down 4.9 %

Shares of NASDAQ FBIO opened at $2.15 on Wednesday. The firm’s 50-day moving average price is $1.89 and its 200-day moving average price is $1.86. Fortress Biotech, Inc. has a 52-week low of $1.36 and a 52-week high of $2.89. The company has a market cap of $59.35 million, a PE ratio of -0.70 and a beta of 1.67.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on FBIO shares. HC Wainwright upped their target price on shares of Fortress Biotech from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. StockNews.com cut Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $13.67.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.